Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Gains from Sales and Divestitures (2023 - 2025)

BioXcel Therapeutics has reported Gains from Sales and Divestitures over the past 3 years, most recently at $7000.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $7000.0 for Q4 2025, up 16.67% from a year ago — trailing twelve months through Dec 2025 was $7000.0 (up 16.67% YoY), and the annual figure for FY2025 was $7000.0, up 16.67%.
  • Gains from Sales and Divestitures for Q4 2025 was $7000.0 at BioXcel Therapeutics, up from $5.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for BTAI hit a ceiling of $69000.0 in Q3 2024 and a floor of $5.0 in Q3 2025.
  • Median Gains from Sales and Divestitures over the past 3 years was $19500.0 (2023), compared with a mean of $29625.6.
  • Peak annual rise in Gains from Sales and Divestitures hit 16.67% in 2025, while the deepest fall reached 99.99% in 2025.
  • BioXcel Therapeutics' Gains from Sales and Divestitures stood at $61000.0 in 2023, then crashed by 90.16% to $6000.0 in 2024, then increased by 16.67% to $7000.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $7000.0 (Q4 2025), $5.0 (Q3 2025), and $14000.0 (Q2 2025) per Business Quant data.